Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Completed · Phase 2 · Has a placebo group

Conditions studied: Pruritus, Atopic Dermatitis

In brief

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Key facts

Study ID

NCT02975206

Run by

Vyne Therapeutics Inc.

People needed

484

Starts

2016-11-01

Expected to finish

2018-02-23

Last updated by the study team

2021-05-20

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, age 13 years or older
• Pruritus prior to and during the initial screening period
• Diagnosis of atopic dermatitis
• Judged to be in good health in the investigator's opinion

You may not qualify if…

• Prior treatment with study drug or similar drug
• Pruritus due to another reason besides atopic dermatitis
• Presence of any medical condition or disability that could interfere with study
• History of hypersensitivity to serlopitant or any of its components
• Currently pregnant or male partner of pregnant female
• Females of childbearing potential who are unable or unwilling to use adequate contraception or who are breast feeding

Where it is running

• Study Site 363 — Birmingham, Alabama, United States
• Study Site 340 — Hoover, Alabama, United States
• Study Site 364 — Glendale, Arizona, United States
• Study Site 334 — Cerritos, California, United States
• Study Site 386 — Encinitas, California, United States
• Study Site 366 — Fountain Valley, California, United States
• Study Site 338 — Los Angeles, California, United States
• Study Site 383 — North Hollywood, California, United States
• Study Site 374 — Oceanside, California, United States
• Study Site 347 — San Diego, California, United States
• Study Site 356 — San Diego, California, United States
• Study Site 333 — San Francisco, California, United States
• Study Site 376 — Santa Monica, California, United States
• Study Site 358 — Denver, Colorado, United States
• Study Site 370 — Jacksonville, Florida, United States
• Study Site 331 — Miami, Florida, United States
• Study Site 348 — Miami, Florida, United States
• Study Site 378 — Miami, Florida, United States
• Study Site 353 — Pinellas Park, Florida, United States
• Study Site 368 — Tampa, Florida, United States
• Study Site 377 — Tampa, Florida, United States
• Study Site 369 — Atlanta, Georgia, United States
• Study Site 349 — Savannah, Georgia, United States
• Study Site 381 — Chicago, Illinois, United States
• Study Site 332 — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.